Revenue Showdown: Eli Lilly and Company vs Walgreens Boots Alliance, Inc.

Eli Lilly vs Walgreens: A Decade of Revenue Growth

__timestampEli Lilly and CompanyWalgreens Boots Alliance, Inc.
Wednesday, January 1, 20141961560000076392000000
Thursday, January 1, 201519958700000103444000000
Friday, January 1, 201621222100000117351000000
Sunday, January 1, 201722871300000118214000000
Monday, January 1, 201821493300000131537000000
Tuesday, January 1, 201922319500000120074000000
Wednesday, January 1, 202024539800000121982000000
Friday, January 1, 202128318400000132509000000
Saturday, January 1, 202228541400000132703000000
Sunday, January 1, 202334124100000139081000000
Monday, January 1, 2024147658000000
Loading chart...

In pursuit of knowledge

Revenue Showdown: A Tale of Two Giants

In the ever-evolving landscape of the pharmaceutical and retail sectors, Eli Lilly and Company and Walgreens Boots Alliance, Inc. have emerged as formidable players. Over the past decade, Eli Lilly has seen its revenue grow by approximately 74%, from $19.6 billion in 2014 to an impressive $34.1 billion in 2023. This growth underscores its strategic focus on innovation and expanding its product portfolio.

Meanwhile, Walgreens Boots Alliance, a titan in the retail pharmacy space, has consistently maintained a robust revenue stream, peaking at $147.7 billion in 2024. Despite the challenges posed by the global pandemic, Walgreens has demonstrated resilience, with a steady revenue increase of around 93% since 2014.

As we look to the future, the missing data for Eli Lilly in 2024 leaves room for speculation. Will they continue their upward trajectory, or will Walgreens further solidify its dominance?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025